Reading time 60 minutes

Aktualisiert – June 27, 2026

Zytostatika (pl. von Zytostatikum) sind natürliche oder synthetische Wirkstoffe, die Zellwachstum und Zellteilung hemmen. Sie manipulieren den Zellzyklus, indem sie die DNA schädigen oder den Zellstoffwechsel stören.

Neben Zytostatika gibt es noch:

• Tyrosine kinase inhibitors
  blockieren spezifische Signalwege, die für das Überleben und Wachstum von Tumorzellen notwendig sind, ohne direkt die Zellteilung zu hemmen.
• Therapeutische monoklonale Antikörper
  zielen auf spezifische Oberflächenstrukturen ab, um Tumorzellen zu markieren oder Signalwege zu blockieren.
• Checkpoint inhibitors
  Immuntherapeutika enttarnen Tumorzellen für das körpereigene Immunsystem.
• Hormone und Antihormone
  Bei hormonabhängigen Tumoren werden Gegenspieler wie Antiöstrogene oder Antiandrogene eingesetzt, um das Tumorwachstum zu eindämmen. 
• Zytokine und Proteasom-Inhibitoren
  greifen in zelluläre Prozesse ein, um das Tumorwachstum zu stoppen. 
• Angiogenese-Hemmer
  unterbinden die Neubildung von Blutgefäßen im Tumor, wodurch dieser mit Nährstoffen unterversorgt wird.

In Summe enthält der Visualisierer 127 Wirkstoffe, darunter Alkylanzien, Antimetabolite, Anthrazykline, Topo-Inhibitoren, Vinca-Alkaloide, Taxane, Monoklonale Antoikörper, Checkpoint-Inhibitoren, CAR-T und andere, sowie Glucocorticoids als unterstützender Wirkstoff.

For the specific R-CHOP chemotherapy for DLBCLDiffuse Llarge b-CL Lymphoma – diffus großzelliges B-Zell-Lymphom) gibt es einen separaten Contribution.

Given the length of this article, it is recommended to use the table of contents to navigate directly to the section of interest.

Für eilige Leser ist die ausführliche Anleitung für den Visualisierer des Chemo – Therapie Konfigurators direkt here, der Visualisierer here reachable.

Please send content-related questions via email to submit.

Anyone affected and – additionally – seeking professional advice can at any time receive individual Beratung und / oder wissenschaftlich fundierte Recherche anfragen.

Foreword

Die Diagnose Krebs ist für die meisten Menschen zunächst ein Schock.

Von einem Moment auf den anderen scheint nichts mehr so zu sein wie zuvor. Sofort entstehen Bilder im Kopf: Chemotherapie, Haarausfall, Übelkeit, Krankenhausaufenthalte, Schmerzen und nicht zuletzt die Angst vor dem, was die Zukunft bringen wird.

Diese Reaktion ist völlig verständlich.

Doch so schwer die Diagnose auch sein mag, eines sollte man sich möglichst früh bewusst machen:

Krebs ist nicht gleich Krebs – und Chemotherapie ist nicht gleich Chemotherapie.

Der Begriff „Krebs“ umfasst viele verschiedene Erkrankungen, die sich hinsichtlich ihres Verlaufs, ihrer Behandlungsmöglichkeiten und Heilungschancen zum Teil erheblich unterscheiden. Gleiches gilt für die unterschiedlichen Formen der Krebsbehandlung.

Ein gutes Beispiel ist der Blasenkrebs: Wird er in einem frühen Stadium entdeckt, erfolgt die Behandlung häufig durch eine lokale Therapie direkt in der Blase. Dabei werden die Wirkstoffe nicht über den gesamten Körper verteilt, sondern wirken überwiegend dort, wo sie benötigt werden. Die typischen Vorstellungen vieler Menschen von einer Chemotherapie, etwa Haarausfall, starke Übelkeit oder eine allgemeine Belastung des gesamten Körpers, treffen in solchen Fällen oft überhaupt nicht zu.

Leider nimmt die Angst nach einer Krebsdiagnose häufig so viel Raum ein, dass sie den Blick auf die tatsächlichen Möglichkeiten der modernen Medizin verstellt. Man sieht zunächst nur den bedrohlichen Teil des Weges vor sich und übersieht leicht, dass es daneben zahlreiche Chancen und Hilfen gibt.

Genau deshalb ist dieser Beitrag entstanden.

Er soll helfen, Unsicherheit durch Wissen zu ersetzen. Nicht, weil Wissen die Erkrankung verschwinden lässt, sondern weil Verständnis dabei helfen kann, Ängste einzuordnen und bessere Entscheidungen zu treffen.

Neben medizinischem Wissen kann dabei auch psychologische oder psychoonkologische Unterstützung eine wichtige Hilfe sein. Viele Menschen erleben nach der Diagnose Phasen von Angst, Überforderung, Niedergeschlagenheit oder großer Unsicherheit. Solche Reaktionen sind normal und kein Zeichen von Schwäche. Gespräche mit psychoonkologisch geschulten Fachkräften können helfen, die seelische Belastung besser zu bewältigen, neue Orientierung zu finden und den eigenen Weg durch die Erkrankung mit mehr Stabilität und Zuversicht zu gehen.

Wer versteht, wie Krebs entsteht, wie Zytostatika wirken und weshalb und wann bestimmte Nebenwirkungen auftreten können, erkennt auch, an welchen Stellen es Möglichkeiten gibt, den Körper sinnvoll zu unterstützen.

Dabei geht es ausdrücklich nicht um Wundermittel oder vermeintliche Geheimtipps. Gerade Menschen mit Krebs werden oft mit gut gemeinten Ratschlägen, fragwürdigen Heilversprechen und teuren Produkten konfrontiert, deren Nutzen bestenfalls unklar ist.

In diesem Beitrag werden deshalb nur Maßnahmen betrachtet, für die wissenschaftliche Erkenntnisse, klinische Erfahrungen oder nachvollziehbare biologische Wirkmechanismen vorliegen. Dazu gehören – je nach Art der Erkrankung und der eingesetzten Therapie – auch bestimmte Nahrungsergänzungsmittel sowie ausgewählte Wirkstoffe aus Pflanzen oder Heilpilzen.

Genauso wichtig ist jedoch die andere Seite der Medaille: Nicht alles, was als „natürlich“ gilt, ist während einer Krebsbehandlung automatisch sinnvoll. Manche Substanzen können die Wirkung einer Therapie sogar beeinträchtigen. Deshalb sollten unterstützende Maßnahmen immer im Zusammenhang mit der jeweiligen Erkrankung und der konkreten Behandlung betrachtet werden.

Eines möchte ich besonders deutlich betonen:

Dieser Beitrag versteht sich als Ergänzung zur medizinischen Behandlung, nicht als Ersatz dafür. Die moderne Onkologie verfügt heute über wirksame Therapien, die jedes Jahr unzähligen Menschen zusätzliche Lebenszeit oder sogar Heilung ermöglichen. Eine enge Zusammenarbeit mit den behandelnden Ärzten bleibt deshalb unverzichtbar.

Wenn dieser Beitrag also dazu beiträgt, Ängste etwas zu reduzieren, Zusammenhänge verständlicher zu machen und Ihnen das Gefühl zu geben, Ihrer Erkrankung nicht hilflos ausgeliefert zu sein, dann hat er seinen Zweck erfüllt.

Nehmen Sie sich die Zeit, die Sie brauchen. Lesen Sie die Abschnitte, die für Sie gerade wichtig sind. Und vergessen Sie bei allem medizinischen Wissen nie:

Eine Krebsdiagnose verändert vieles – aber sie nimmt Ihnen nicht die Möglichkeit, informiert, aktiv und hoffnungsvoll nach vorne zu schauen.

Ich wünsche Ihnen Kraft, Zuversicht und vor allem einen erfolgreichen Weg durch die Behandlung.

Therapy goals

In chemotherapy, cytostatics are used to treat cancer. They primarily attack cells that divide particularly rapidly (tumor, blood, intestinal epithelial, and skin cells), but are also administered for autoimmune diseases.

The crux of chemotherapeutics

The drawback of chemotherapeutic agents, also known as cytotoxic drugs, is that they cannot distinguish between good cells (blood, intestinal epithelial, skin, and hair cells) and bad cells (tumor cells), which explains the side effects that occur during chemotherapy.

The relative variety of available cytostatics results from different types of cancer, the need to develop therapies adapted to the cancer stage and the patient's general condition, but also to largely avoid resistance.

Cancer cells, like all living beings, have the need to survive. Therefore, like bacteria, viruses, or fungi, they adapt to the conditions essential for survival. The most resilient cells replicate again, and from that, the most resilient survive. With each cycle, increasingly resistant cells emerge.

This is why combination therapies using multiple active agents are often employed to minimize the development of resistance, to attack cancer cells on multiple levels considering their specific mechanisms, and to induce cell death (apoptosis).

Unlike classic chemotherapies, monoclonal antibodies, immunotherapies, and other targeted therapies can often attack tumor cells much more selectively. They spare many healthy, rapidly dividing cells better than classic chemotherapy, but are not entirely free of effects on normal cells or the immune system.

The trend in modern oncology is increasingly moving towards such targeted and immunological procedures because they enable better efficacy with an often more favorable side effect profile for many tumor types.

Monoclonal Antibody and Immunotherapy vs. Chemo

Monoclonal antibodies and modern immunotherapies generally cause less non-specific cell damage than classical chemotherapies. However, specific long-term side effects occur.

In antibody therapies, organ-specific effects such as cardiotoxicity, immunodeficiencies, or vascular damage are dominant.

With checkpoint inhibitors (immunotherapy), long-term side effects arise primarily from excessive or misdirected immune responses.

The most common permanent damage affects the thyroid gland, pituitary gland, adrenal glands, and pancreas, but can also affect joints, lungs, heart, nerves, or kidneys.

Many of these changes resemble classical autoimmune diseases and can persist for life. Therefore, although immunotherapies are often considered better tolerated than chemotherapies, they are not considered free of relevant long-term consequences.

The patient is in a lose-lose situation, as the saying goes, even though the nature of the damage is completely different:

Typical late side effects of chemotherapy:

• Neuropathies
• Second primary malignancies
• Heart damage
• Fertility disorders

Typical long-term side effects of immunotherapy:

• Autoimmune diseases
• Hormone deficiencies
• Chronic inflammation
• Organ fibrosis

What is apoptosis?

Apoptosis is the process that causes a cell to die. It occurs in a controlled and biologically „clean“ manner. There are four types of „cell death“:

• Programmer Cell death
  through strong or irreparable DNA damage, activation of control mechanisms (tumor suppressor protein p53 („guardian of the genome“, etc.)
• Mitotic Catastrophic cell death
  the cell continues to divide (mitosis) despite damage, faulty chromosome segregation, followed by „chaotic“ cell death
• Senescence Cellular senescence
  A cell remains permanently divisible, but dies out after a certain period of time due to „old age.“

Active ingredients

Etwa 60 Zytostatika stehen bei der Krebs-Therapie zur Wahl. Sie untergliedern sich in folgende Wirkstoffgruppen:

Alkylating agents

Alkylating agents transfer alkyl groups to DNA. By altering the DNA’s structure, they prevent it from functioning normally and dividing, thereby inducing apoptosis in the cancer cell.
Structural changes can include, for instance, cross-linking of DNA strands, modification of individual bases, strand breaks, and inhibition of DNA replication and transcription.

• Bendamustine (Ribomustin®)
• Busulfan (Busilvex®, discontinued)
• Carmustine (BiCNU®)
• Chlorambucil (Leukeran®)
• Chlormethin (Ledaga®)
• Cyclophosphamide (Endoxan®)
• Dacarbazine (Dacin®)
• Ifosfamide (Holoxan®)
• Lomustine (Ceenu®, no longer available)
• Lurbinectedin (Zepzelca®)
• Melphalan (Alkeran®)
• Procarbazine (Natulan®)
• Streptozocin (Zanosar, no longer available)
• Temozolomide (Temodar®)
• Treosulfan (Trecondi®)

Alkylating agents and dietary supplements

Tumor cells can partially detoxify alkylating agents by:

• Glutathione
• Glutathione S-transferases

For this reason, dietary supplements that can increase glutathione levels are sometimes viewed with skepticism:

• N-Acetylcysteine
• Alpha-lipoic acid
• high-dose vitamin C (indirect)
• other sulfur-containing compounds

The theoretical concern is: More glutathione → stronger detoxification of the alkylating agent → lower tumor efficacy.

However, this is not clearly documented clinically for all combinations. At physiological dosages, dietary supplements are often considered less problematic:

• Vitamin D
• Selenium (especially in case of deficiency)
• Coenzyme Q10
• common multivitamins

So far, there is no strong evidence for a reduction in the efficacy of alkylating agents.

Conclusion

With alkylants, the focus is less on the direct neutralization of ROS and more on their potential influence on cellular detoxification mechanisms, particularly the glutathione system.

Antimetabolite / Nucleic Acid Analogues

Analogs are chemical compounds that are structurally similar to the natural parent compound or have a similar charge distribution. As a result, they can be recognized and bound by the same enzymes or receptors. In cancer therapy, such analogs can disrupt normal metabolic processes. Nucleoside and nucleotide analogs, for example, are incorporated into DNA and can lead to chain breaks or inhibition of DNA synthesis. This impairs the division of cancer cells and ultimately often triggers apoptosis (programmed cell death).

• Azacitidine (Vidaza®)
• Capecitabine (Xeloda®)
• Cladribine (Litak®)
• Cytarabine (Cytosar®)
• Fludarabine (Generics, Original: Fludara®)
• 5-Fluorouracil (e.g. Verumal®)
• Gemcitabine (Generics, Original: Gemzar®)
• Mercaptopurine (Puri-Nethol®)
• Nelarabine (Atriance®)
• Thioguanine (Lanvis®)

Antimetabolites / Nucleic Acid Analogs and Nutritional Supplements

vitamin C

For physiological dosages, there is no clear evidence of reduced efficacy of antimetabolites. Primarily discussed are:

• high-dose oral applications
• intravenous high-dose therapies

However, the data situation remains inconsistent.

Vitamin E

The theoretical probability of interaction is considered low. Vitamin E has been investigated primarily with regard to:

• Mucositis
• Neuropathy
• general compatibility

Selenium

Selenium is often used in connection with:

• Mucositis
• Fatigue
• Bone marrow toxicity

discussed. A significant attenuation of the effect of antimetabolites has not yet been convincingly demonstrated.

Coenzyme Q10

For antimetabolites, there are few indications of problematic interactions. Their theoretical relevance is generally considered low.

N-Acetylcysteine (NAC)

• has an antioxidant effect,
• indirectly increases glutathione availability,
• influences various redox signaling pathways.

This raises at least theoretical concerns, especially when combined with active ingredients whose cell death mechanisms are partly mediated by oxidative stress.

However, the evidence for classical antimetabolites is significantly weaker than for alkylating agents or anthracyclines.

Special case Methotrexate

The gift of:

• Folic acid
• Folic acid (Leucovorin)

is a partial integral component of certain methotrexate protocols.

This is not an unwanted interaction, but a purposefully implemented protective mechanism.

This shows that with antimetabolites, the question often relates more to the Metabolic pathway of the active ingredient affects as its ROS dependency.

Conclusion

Antimetabolites and nucleic acid analogs primarily exert their antitumor effects by interfering with nucleic acid biosynthesis and the cell cycle. Since oxidative stress does not play a central role in this process, a direct weakening of efficacy by antioxidant dietary supplements appears biologically less plausible. More relevant are possible interactions at the level of drug metabolism or specific metabolic pathways.

Folic acid antagonists

Folic acid antagonists (antifolates) are cancer drugs that inhibit the action of folic acid. Since folic acid is needed for the production of DNA building blocks (purines and thymine), its inhibition disrupts DNA synthesis.

Folic acid antagonists are structurally similar to folic acid and compete with it for important enzymes. They particularly inhibit enzymes that are necessary for the formation of nucleotides. By inhibiting DNA synthesis, rapidly growing cells can no longer divide and die.

For example, methotrexate inhibits the enzyme dihydrofolate reductase (DHFR), which is essential for the formation of active folic acid.

Folic acid antagonists are a form of antimetabolites and act as folic acid analogs, as they structurally resemble folic acid but block its function.

• Methotrexate (Generics)
• Pemetrexed (Alimta®)
• Raltitrexed (Tomudex®)

Folic acid antagonists and dietary supplements

Less folate availability → less DNA synthesis → less cell division.

So, the critical metabolic pathway is the Folate metabolism, not primarily the redox system.

With methotrexate

The assessment depends on the therapy context:

Low-dose methotrexate (e.g., Rheumatology):

• Folic acid is often supplemented intentionally.
• Reduction of side effects.
• Mostly without significant loss of efficacy.

High-dose methotrexate in oncology:

• Independent folic acid supplementation can be problematic.
• Instead, a precisely planned administration of folic acid (Leucovorin Rescue) is carried out.

Therefore, additional folate supplementation in oncological methotrexate protocols should fundamentally only be carried out according to the protocol.

Folic acid (Leucovorin)

Leucovorin – Interestingly, folic acid is not only a protective agent but is also used therapeutically.

Depending on the context, she can:

• Reduce methotrexate toxicity
• even amplify the effect of 5-FU

Vitamin B12

For pemetrexed, vitamin B12 supplementation is even part of the standard for many treatment protocols. So there is no contradiction between chemotherapy and supplementation here.

Goals

• less hematologic toxicity
• less mucositis
• better compatibility

Antioxidant NEM

Examples:

• vitamin C
• Vitamin E
• Selenium
• Coenzyme Q10

There is no strong evidence for antifolates that these substances would directly abolish the main effect, as the antitumor effect is based on folate depletion and disturbed nucleotide synthesis, not on ROS-induced cell damage.

That's why antioxidant nutritional supplements are usually less critically discussed with antifolates than with anthracyclines.

N-acetylcysteine and glutathione-boosting supplements

At:

• NAC
• Alpha-lipoic acid

the question is more about general redox modulation and possible effects on apoptotic signaling pathways.

However, the theoretical relevance appears to be lower compared to alkylating agents or platinum compounds.

Conclusion

For folic acid antagonists, potential interactions with folate metabolism are of primary concern. While antioxidant supplements are usually of secondary importance due to their mechanism of action not being primarily ROS-mediated, folic acid, folinic acid, and vitamin B12 can directly influence the efficacy and tolerability of these agents and must therefore be evaluated in the context of the respective therapeutic protocol.

Halichondrin / Mitotic Inhibitor

They attack the microtubules (tubular structures belonging to the cytoskeleton, made of the protein tubulin, which dynamically stabilize the cell and serve intracellular transport) of the spindle apparatus (forms during mitosis from microtubules, serves to distribute duplicated chromosomes to daughter cells) by inhibiting microtubule growth (polymerization). Consequently, a functional spindle apparatus cannot form, and cell division cannot be completed. As a result, apoptosis is initiated.

• Paclitaxel stabilizes microtubules, thereby impairing their necessary dynamics
• vincristine already inhibits the assembly of microtubules
• Eribulin (Halaven®) binds to the growing ends of microtubules, preventing further elongation (polymerization).

Many tumor cells react to microtubule inhibition with:

• Oxidative stress
• mitochondrial changes
• Activation of apoptotic signaling pathways

These processes are considered more as downstream effects as the primary mechanism of action.

Halichondrine / Mitotic inhibitor and NEM

vitamin C

• Physiological dosages: low theoretical relevance.
• High-dose applications: unclear data.

Vitamin E

• No established clinically relevant interaction with eribulin is known.
• It is discussed more in the context of neuropathy.

Selenium

• No specific counteraction to the mechanism of action is expected.
• Primarily investigated for deficiency conditions or to reduce side effects.

Coenzyme Q10

• Theoretically low probability of interaction.
• The main interest lies more in mitochondrial protection.

N-Acetylcysteine (NAC)

Here lies the greatest theoretical uncertainty:

• strong influence on the cellular redox system,
• Influence on glutathione,
• Modulation of Apoptotic Signaling Pathways.

However, whether this has a clinically relevant impact on the efficacy of eribulin is not convincingly proven.

Alpha-lipoic acid

Similar considerations as with NAC, though also without clear clinical evidence of loss of efficacy.

Neuropathy as a special aspect

With eribulin, the peripheral neuropathy a significant side effect.

Therefore, NMEs are often discussed not for tumor control, but for support in neurotoxicity:

• Alpha-lipoic acid
• B Vitamins
• Acetyl-L-Carnitine (although the evidence is partly contradictory)

Here, one must always distinguish between:

1. Protection of healthy nerve cells
2. potential influence on tumor effect

to be weighed.

Conclusion

Halichondrins, like eribulin, primarily exert their antitumoral effect by inhibiting microtubule dynamics and blocking mitosis. Since oxidative stress is not among their central mechanisms of action, a direct reduction in efficacy due to antioxidant dietary supplements appears biologically less plausible. Potential interactions more likely involve downstream redox and apoptosis signaling pathways, for which, however, only limited clinical evidence is available to date.

Immunotherapy

Immunotherapy activates or regulates the immune system so that it can specifically recognize and destroy tumor cells. Besides checkpoint inhibitors, there are three approaches:

• CAR-T cell therapy
  T-cells taken from the patient are genetically modified in the lab
  – will be returned to the patient
  – recognize tumor cells specifically
• Therapeutic antibodies
  – bind directly to tumor cells
  – mark for the immune system or
  – block growth signals
• . Cytokine therapy (rare)
  – e.g. interleukins or interferons
  – enhance immune activity

Immunotherapy and dietary supplements

Vitamin D

Vitamin D holds a special position.

• influences T-cells
• influences dendritic cells
• regulates T cells

A deficiency is often seen as unfavorable. Correcting a deficiency is usually not considered problematic.

Selenium

Selenium is relevant for numerous immune functions. Discussed are:

• T-cell function
• antioxidant protection
• Inflammation regulation

However, the data on combinations with checkpoint inhibitors is limited.

vitamin C

There is even preclinical data suggesting potential support for anti-tumor immune responses. However, the clinical evidence is not yet sufficient for general recommendations.

Which NEM could theoretically be more problematic?

Potent immunosuppressive drugs

Not primarily antioxidants, but substances with a pronounced immunomodulatory effect. The theoretical concern is a reduction in the desired immune activation.

However, this applies more to medications than to classic dietary supplements.

High-dose plant extracts

Examples:

• Curcumin
• highly concentrated polyphenols
• Certain medicinal mushroom preparations

Immunomodulatory effects can occur here, which are difficult to predict. The evidence is often limited.

Conclusion

In immunotherapy, potential interactions between antioxidant dietary supplements and the immune system are of primary concern. Since the antitumor effect is primarily mediated by the activation of immune cells and not by the induction of oxidative stress, a direct weakening of the therapy by classical antioxidants appears less plausible. More relevant are possible immunomodulatory and inflammation-regulating effects of individual supplements, which should be evaluated depending on the active substance, dosage, and clinical context.

Monoclonal antibodies

Monoclonal antibodies are identical antibodies created in a laboratory that specifically bind to an antigen, marking, blocking, or directly attacking tumor cells in cancer therapy.

The effect is based on four possible target directions:

• Tumor cell marking
  - the antibodies bind to tumor antigens
  – the immune system recognizes the marked cell better
  – Result: Destruction by immune cells
• Blockade of growth signals
  – Receptors on tumor cells are blocked
  – no more growth stimulation
  Result: Tumor grows slower or stops
• Immune system activation (ADCC)
  – Antibodies „mark“ the tumor cell
  Killer cells (NK cells) attack
  – Result: Cell death
• Transport of active ingredients
  Antibodies carry, for example, chemtoxins or radioisotopes
  targeted delivery to tumor cells

Monoclonal Antibodies and Dietary Supplements

vitamin C

For physiological dosages, there is no established evidence that they weaken the effects of trastuzumab, rituximab, or bevacizumab.

Vitamin E

Similarly low theoretical relevance.

Selenium

Is discussed more in terms of immune function and side effect management.

Coenzyme Q10

Supportive use is occasionally considered, particularly for therapies with potential cardiotoxicity (e.g., trastuzumab). However, this does not result in a definitive recommendation.

NAC and Alpha-Lipoic Acid

However, a clear clinical relevance has not yet been demonstrated. Theoretical considerations exist regarding:

• Redox signaling pathways
• Immune cell function
• Apoptotic pathways

Special features of immune-mediated mechanisms

The immune system plays an important role in some antibodies, for example in

• Rituximab
• Trastuzumab

tumor cells are partially over

• natural killer cells (NK cells)
• Macrophages
• Complement system

Eliminated.

Therefore, in antibody therapies, it is often more important to ask: Does the nutraceutical influence the immune response?

Special case Antibody-Drug Conjugates (ADCs)

Examples:

• Trastuzumab Emtansine
• Trastuzumab deruxtecan

Here, the coupled cytotoxic active substance must also be considered. The interaction assessment is then based not only on the antibody but also on the „payload“ (e.g., microtubule inhibitor or topoisomerase inhibitor).

Conclusion

For monoclonal antibodies, a direct impairment of anti-tumor efficacy by antioxidant dietary supplements is biologically less plausible, as their mechanism of action usually relies on the specific blockade of target structures or the activation of immune-mediated effector mechanisms. Potential interactions therefore relate more to the immunomodulatory effects of individual supplements than to their antioxidant properties.

Platinum compounds

While alkylating agents distribute alkyl groups onto the DNA, the platinum atom forms bonds between the two DNA strands (crosslinking), causing a deformation of the DNA that makes correct separation impossible: replication and transcription are disrupted, and – if DNA repair mechanisms fail – apoptosis of the cell is triggered.

• Carboplatin (Paraplatin®, Generika)
• Cisplatin (Generics)
• Oxaliplatin (Generika, Original: Eloxatin®)

Platinum compounds also lead to:

• Mitochondrial dysfunction
• Formation of reactive oxygen species (ROS)
• oxidative damage in normal tissues

In particular, the following side effects are partly associated with oxidative stress:

Cisplatin

• Nephrotoxicity
• Ototoxicity
• Neurotoxicity

Oxaliplatin

• peripheral neuropathy

This is why the idea arose to use antioxidants to reduce side effects.

The central dilemma

The crucial question is: Does the antioxidant protect only healthy tissue or the tumor cell as well? The evidence on this very point is not clear to date.

Platinum compounds and NEM

Selenium

Selenium is among the most studied micronutrients in relation to cisplatin. The studies examined:

• Nose guard
• antioxidant protection
• Compatibility

The data suggests a potential benefit regarding side effects rather than a relevant reduction in efficacy.

vitamin C

The data is contradictory. Being discussed are:

• antioxidant effects
• Influence on cisplatin-induced ROS
• Possible protective effect for healthy tissue

A clear clinical recommendation cannot be derived from this.

Vitamin E

Vitamin E has been particularly associated with:

• Cisplatin-induced neuropathy
• Oxaliplatin-induced neuropathy

examined.

Partially, favorable effects on neurotoxic side effects have been described.

Alpha-lipoic acid

Particularly interesting about:

• Oxaliplatin-induced neuropathy
• Cisplatin-induced neuropathy

However, the results of clinical studies are not uniform.

NAC

NAC has the highest theoretical relevance here:

• Increasing glutathione availability
• direct redox modulation
• Possible detoxification of platinum-induced cell damage

Theoretically, this could protect both normal cells and tumor cells. Therefore, NAC is often assessed more cautiously than selenium or vitamin D.

Coenzyme Q10

It is occasionally discussed for its mitochondrial protective effect. The evidence is currently limited.

The special role of glutathione

With platinum compounds, the antioxidant effect is not the only important factor. What is also crucial is: Glutathione can chemically bind and detoxify platinum compounds.

Tumor cells with high glutathione levels often show:

• lower cisplatin sensitivity
• Resistance development

Therefore, NEM that strongly influence the glutathione system are viewed with particular criticality. These include, above all:

• NAC
• sulfur-containing compounds
• partial alpha-lipoic acid

Classification of NEM according to theoretical relevance

Rather low theoretical probability of interaction

• Vitamin D
• Selenium (physiological dosage)
• Coenzyme Q10

Medium theoretical relevance

• vitamin C
• Vitamin E
• Alpha-lipoic acid

Higher theoretical relevance

• N-Acetylcysteine
• other glutathione-boosting strategies

Conclusion

Platinum compounds exert their antitumor effect primarily through the formation of DNA adducts and cross-links. While oxidative stress contributes to various side effects, it is not the central antitumor mechanism of action. Antioxidant dietary supplements are therefore primarily investigated with regard to the reduction of therapy-associated toxicities. However, supplements that influence the glutathione system deserve special attention, as it is involved in the cellular detoxification of platinum compounds and potentially also in resistance mechanisms.

Proteasome inhibitors

The proteasome breaks down damaged, misfolded, or no longer needed proteins. Proteasome inhibitors block this process, causing the cell to come under severe stress due to the further accumulation of „protein waste,“ disrupting signaling pathways and initiating apoptosis.

• Bortezomib (Velcade®)

Oxidative stress particularly contributes to cell death in myeloma cells.

Unlike with anthracyclines, while ROS is not the sole mechanism, it is significantly more involved than with antimetabolites or antimitotic agents.

The Special Case of Bortezomib

For Bortezomib, there is a known and well-documented interaction with certain antioxidants. Bortezomib contains a Boric acid group. This allows some substances to interact chemically directly with the active ingredient. Particularly discussed were:

• high-dose vitamin C
• EGCG from green tea
• other polyphenols with boronic acid affinity

In preclinical studies, the efficacy of bortezomib could be partially attenuated. Therefore, caution is often advised with high-dose green tea extracts or high-dose vitamin C when using bortezomib.

Proteasome inhibitors and NEM

vitamin C

Special attention to bortezomib.

The discussion is based not only on antioxidant properties, but on possible direct chemical interactions.

→ higher theoretical relevance than with many other tumor therapies.

EGCG (Epigallocatechin gallate - Green tea extract)

This is arguably the classic example of a potentially relevant interaction with bortezomib. The reason is primarily chemical, not solely antioxidant.

NAC

• Increases Glutathione
• influences redox signaling pathways

Since oxidative stress is involved in the mechanism of proteasome inhibitors, a theoretical attenuation appears more biologically plausible than with antimetabolites. However, this is not clearly documented clinically.

Alpha-lipoic acid

Similar considerations as with NAC. Particularly relevant due to their use in polyneuropathies.

Vitamin E

Is discussed primarily with regard to neuroprotection. The evidence for a relevant attenuation of effect is limited.

Selenium

No established direct interaction known.

Coenzyme Q10

Theoretically low to moderate relevance. The data situation is limited.

Neuropathy as a central theme

Proteasome inhibitors often cause:

• peripheral neuropathies
• Fatigue
• Mitochondrial dysfunction

Therefore, NMEs are often used for side effect control. Typical candidates are:

• Alpha-lipoic acid
• Vitamin E
• B Vitamins
• Acetyl-L-Carnitine

This again brings up the classic trade-off: protecting healthy nerve cells versus potentially weakening anti-tumor mechanisms.

Conclusion

In addition to inhibiting the proteasome, proteasome inhibitors induce cellular stress and oxidative stress, which can contribute to the apoptosis of malignant cells. Therefore, a weakening of therapy by strongly redox-modulating dietary supplements appears biologically more plausible than with antimetabolites or antimitotic agents. Particular attention should be paid to certain antioxidants and polyphenols in bortezomib, especially high-dose vitamin C and EGCG, as direct chemical interactions with the active substance are discussed in addition to antioxidant effects.

Taxane

Taxanes belong to the group of antimitotic agents and stabilize microtubules to such an extent that no further remodeling (shortening, lengthening) is possible, thus preventing the completion of mitosis and leading to cell death.

• Cabazitaxel (Jevtana®)
• Docetaxel (Taxotere®)
• Paclitaxel (Taxol®)

Unlike anthracyclines, the formation of reactive oxygen species (ROS) is not a central mechanism of action. However, numerous experimental studies show that taxanes also:

• can increase oxidative stress
• affect mitochondrial function
• modulate redox-dependent signaling pathways

ROS appear to be more of an accompanying reinforcement mechanism rather than the primary cause of tumor cell killing. Therefore, a relevant weakening by antioxidants appears fundamentally possible biologically, but is mostly less plausible than with anthracyclines.

Taxanes and dietary supplements

The Special Case of Neuropathy

For taxanes, the focus of the discussion on nutritional supplements is less on the tumor effect and more on side effect control.

Taxanes commonly cause:

• peripheral neuropathies
• Sensory disturbances
• Pain
• Fatigue
• Mitochondrial dysfunction in nerve cells

This is why numerous dietary supplements are being studied for the prevention or treatment of these conditions. Typical candidates:

• Alpha-lipoic acid
• B Vitamins
• Acetyl-L-Carnitine
• Vitamin E
• Omega-3 fatty acids

Herein lies the well-known balancing act: Protection of healthy nerve cells versus possible influence on cellular stress mechanisms contributing to tumor cell killing.

vitamin C

Vitamin C has antioxidant properties. Unlike bortezomib, there is no known direct chemical interaction for taxanes.

While a relevant reduction in efficacy appears theoretically possible, especially at very high doses, it is not convincingly substantiated clinically.

low to medium theoretical relevance.

N-Acetylcysteine

NAC increases intracellular glutathione and influences redox signaling pathways. Since taxanes partially induce oxidative stress, it has been discussed whether NAC could weaken their efficacy.

Animal experimental and cell biology data provide some indications for this, but clinical evidence is limited.

→ moderate theoretical relevance.

Alpha-lipoic acid

Alpha-lipoic acid has an antioxidant effect and is often used for polyneuropathies. Since taxane-induced neuropathies are a common problem, it is a particularly frequently discussed dietary supplement.

A clinically relevant weakening of the tumor effect has not been convincingly demonstrated so far.

low to medium theoretical relevance.

Vitamin E

Vitamin E has been repeatedly investigated for the prevention of taxane-induced neuropathies. The results are inconsistent.

A relevant impairment of anti-tumor efficacy has not been established to date.

low to medium theoretical relevance.

Selenium

There are no established direct interactions for selenium with taxanes.

The available data does not indicate a relevant attenuation of efficacy.

low theoretical relevance.

Coenzyme Q10

Coenzyme Q10 influences mitochondrial energy production and has antioxidant effects.

Since mitochondrial changes can be involved in the effects and side effects of taxanes, there is some theoretical relevance. However, clinical evidence of relevant interactions is limited.

low to medium theoretical relevance.

Omega-3 fatty acids

Omega-3 fatty acids are often used for fatigue, inflammatory processes, and general supportive therapy.

A relevant weakening of the taxane effect has not yet been established.

low theoretical relevance.

Acetyl-L-Carnitine

Acetyl-L-carnitine has long been studied for neuropathy prophylaxis. However, several studies yielded conflicting results; in some cases, even a worsening of neuropathic symptoms was observed.

The discussion primarily concerns the side effects, not the tumor efficacy.

→ Low interaction relevance, but special caution regarding neuropathies.

Conclusion

Taxanes primarily work by stabilizing microtubules and blocking mitosis. Although taxanes can also induce oxidative stress and mitochondrial changes, ROS are not considered a central mechanism of action as they are with anthracyclines. Therefore, a weakening of therapy by antioxidant dietary supplements appears biologically less plausible than with anthracyclines or, in some cases, proteasome inhibitors. Dietary supplements that significantly influence the cellular redox status, particularly NAC and high-dose vitamin C, receive special attention. However, the clinical evidence for a relevant weakening of efficacy is limited overall. Taxanes are therefore among the tumor therapies with a rather low to moderate theoretical probability of interaction with antioxidative dietary supplements.

Topoisomerase inhibitors

The intertwined DNA strands become „stressed“ during copying for cell division. Topoisomerases are enzymes that cut the DNA at one point, allowing it to relax, and then reassemble it correctly.

Topoisomerase inhibition is the blockage of enzymes that relieve DNA strand tension. This results in DNA strand breaks, prevents replication, and often leads to cell death via apoptosis.

• Amsacrine (Amsidyl®, discontinued)
• Daunorubicin (Daunoblastin®)
• Etoposide (Vepesid®)
• Irinotecan (Campto®)
• Topotecan (Hycamtin®)

Unlike anthracyclines, oxidative stress is not the primary mechanism. However, numerous experimental investigations show that:

• DNA damage can secondarily generate ROS
• mitochondrial stress responses are activated
• Redox signaling pathways can be involved in apoptosis

ROS thus potentially contribute to the overall effect but are not at the center of the mechanism of action.

Topoisomerase inhibitors and dietary supplements

The Special Case of Etoposide

For etoposide, there is interesting preclinical data. Part of the cytotoxicity appears to be due to:

• oxidative DNA damage
• ROS formation
• Mitochondrial dysfunction

to be strengthened.

In cell culture models, some antioxidants were able to partially attenuate these effects. However, the clinical significance remains unclear.

Unlike with bortezomib, there is no established direct chemical interaction with vitamin C or green tea polyphenols.

vitamin C

Vitamin C can scavenge free radicals and reduce oxidative DNA damage. Since the main effect of topoisomerase inhibitors is based on DNA strand breaks, a relevant weakening of the effect appears less likely than with anthracyclines.

At very high dosages, a theoretical possibility of interaction remains.

low to medium relevance.

N-Acetylcysteine

NAC increases intracellular glutathione levels. Since oxidative stress can contribute to the amplification of DNA damage, a biological interaction appears plausible.

Preclinical studies show partly protective effects against etoposide-induced oxidative stress.

Clinical evidence of relevant therapeutic attenuation is largely lacking.

→ moderate theoretical relevance.

Alpha-lipoic acid

Alpha-lipoic acid influences redox systems and has an antioxidant effect. A relevant impairment of its main DNA-damaging effect has not been convincingly demonstrated to date.

low to medium relevance.

Vitamin E

Vitamin E protects cell membranes from lipid peroxidation.

Since the main effect of topoisomerase inhibitors is not ROS-dependent, a relevant interaction appears rather limited.

low relevance.

Selenium

No established direct interaction known.

The available data does not indicate a relevant attenuation of the effect.

low relevance.

Coenzyme Q10

Coenzyme Q10 influences mitochondrial functions and oxidative stress.

A theoretical interaction is conceivable, but clinical evidence is very limited.

low to medium relevance.

EGCG (Green Tea Extract)

Unlike bortezomib, no established direct chemical interaction is known.

Despite its antioxidant and cell-signaling modulatory properties, EGCG is nevertheless occasionally discussed.

low to medium relevance.

Gastrointestinal side effects as a specialty

In particular, irinotecan frequently causes:

• Severe diarrhea
• Mucositis
• Weight loss
• Fatigue

Therefore, various NMEs and supportive measures are being investigated, including:

• Glutamine
• Omega-3 fatty acids
• Probiotics
• Zinc

Here, compatibility is usually the main focus, not the question of reduced efficacy.

Conclusion

Topoisomerase inhibitors primarily act by stabilizing topoisomerase-DNA complexes, resulting in the accumulation of DNA strand breaks. Although oxidative stress and mitochondrial dysfunction can contribute to the cellular response, they are not considered the central mechanisms of action. Therefore, weakening of therapy through antioxidant dietary supplements appears biologically less plausible than with anthracyclines, platinum compounds, or proteasome inhibitors. Substances with strong redox-modulating properties, such as NAC or high-dose vitamin C, seem most relevant, although the clinical evidence for a relevant impairment of antitumoral efficacy is limited overall. Topoisomerase inhibitors thus belong to the classes of chemotherapy with a low to moderate theoretical probability of interaction with antioxidant dietary supplements.

Tyrosine kinase inhibitors

Tyrosine kinase inhibitors are targeted drugs that block overactive or altered tyrosine kinases, thereby interrupting the signaling pathways for tumor cell growth, division, and survival.

• Imatinib (chronic myeloid leukemia (CML) - Gleevec®)
• Erlotinib (Forms of lung cancer – Tarceva®)
• Osimertinib (e.g., EGFR-mutated lung cancers – Tagrisso®)
• Sunitinib (including renal cell carcinoma – Sutent®)

A practical example of CML treatment with imatinib. Before its introduction, the disease was often life-threatening; today, many affected individuals can live for decades with a good quality of life because the medication specifically inhibits the disease-causing BCR-ABL fusion protein.

Although ROS can be involved in downstream signaling pathways, they are usually not a central mechanism of action.

Therefore, a relevant attenuation by classical antioxidants appears biologically significantly less plausible than with anthracyclines, platinum compounds, or proteasome inhibitors.

Pharmacokinetic interactions

At TKIs, the focus is not on antioxidant effects, but on changes in:

• Resorption
• Metabolism
• Transport proteins

Many TKIs are metabolized by the CYP3A4 enzyme system. This means that certain supplements can increase or decrease drug levels. Therefore, for TKIs, pharmacokinetic interactions are usually more important than antioxidant properties.

Tyrosine kinase inhibitors and NME

Special case: Green tea and polyphenols

Green tea extracts and EGCG are often discussed. Not because of their antioxidant effects, but because they:

• drug transporter can influence
• can modulate CYP enzymes
• can alter the absorption of individual medications

The clinical relevance varies depending on the TKI and is often not clear. However, unlike with bortezomib, there is no known direct chemical inactivation.

vitamin C

No established direct interactions between vitamin C and TKIs are known.

A relevant reduction in effect via antioxidative mechanisms appears biologically implausible.

low relevance.

N-Acetylcysteine

NAC affects redox systems and glutathione.

Since ROS does not play a central role in most TKIs, a relevant interaction is unlikely.

low relevance.

Alpha-lipoic acid

No established direct interaction known.

Theoretical implications for signaling pathways are conceivable, but not clinically proven.

low relevance.

Vitamin E

There is no convincing evidence that vitamin E significantly weakens the effect of TKIs.

low relevance.

Selenium

No established interaction known.

low relevance.

Coenzyme Q10

Coenzyme Q10 is often used for fatigue or cardiovascular support.

So far, no relevant potency reduction of TKIs has been established.

low relevance.

EGCG (Green Tea Extract)

Special attention due to possible effects on:

• CYP Enzyme
• Drug transporter
• Resorption

The issue concerns pharmacokinetics rather than antioxidant effects.

medium relevance.

St. John's Wort

Although not a classic antioxidant, St. John's wort is particularly important for TKIs.

It can strongly induce CYP3A4 and thereby significantly lower the drug levels of numerous TKIs.

→ high clinical relevance.

Specific features of individual TKIs

EGFR inhibitors

(e.g., Erlotinib, Gefitinib, Osimertinib)

More important than antioxidants here are:

• Acid blockers
• Malabsorption
• CYP Interactions

VEGFR and Multikinase Inhibitors

(e.g., Sunitinib, Sorafenib, Pazopanib)

Here are occasionally discussed:

• Coenzyme Q10
• Omega-3 fatty acids
• Antioxidants for fatigue reduction

There is so far no evidence of a relevant reduction in efficacy.

Conclusion

Tyrosine kinase inhibitors work by specifically inhibiting oncogenic signaling pathways and generally do not rely on oxidative stress as a primary anti-tumor mechanism. Therefore, a reduction in their efficacy due to antioxidant supplements appears biologically much less plausible than with many classic chemotherapeutics. Pharmacokinetic interactions, particularly via CYP3A4, drug transporters, and absorption mechanisms, are of greater practical importance. While Vitamin C, Vitamin E, NAC, alpha-lipoic acid, or Coenzyme Q10 usually have only minor theoretical relevance, substances such as St. John's wort and potentially high-dose green tea extracts can cause clinically significant changes in drug levels. TKIs are therefore among the tumor therapy classes with the lowest theoretical probability of interaction with antioxidant supplements.

Vinca alkaloids

Vinca alkaloids bind to tubulin and inhibit the formation of microtubules. This prevents the spindle apparatus from forming, chromosomes cannot be separated, and cell division is halted. This ultimately leads to apoptosis of the cancer cell.

• Vinblastine (Velbe®)
• Vincristine (Generic)
• Vindesin (Eldisine®)
• Vinorelbine (Navelbine®)

While ROS can form secondarily, they are not considered a significant contributing factor.

Therefore, a weakening by classical antioxidants appears fundamentally less plausible than with anthracyclines or platinum compounds.

Vinca alkaloids and dietary supplements

The clinically most important point - neurotoxicity

In vinca alkaloids, neuropathy is much more prominent than potential antioxidative interactions. Vincristine, in particular, frequently causes:

• peripheral neuropathies
• Paresthesia
• neuropathic pain
• autonomic neuropathies
• Gastrointestinal motility disorders

Therefore, numerous NMEs are discussed for neuroprotection. Typical candidates:

• Alpha-lipoic acid
• Vitamin E
• B Vitamins
• Acetyl-L-Carnitine
• Omega-3 fatty acids

This is where the balancing act arises again: Protection of healthy nerve cells versus theoretical influence of cellular stress responses.

vitamin C

There are no established direct chemical interactions with Vitamin C for Vinca alkaloids.

Since ROS are not part of the main mechanism of action, a relevant weakening seems biologically implausible.

low relevance.

N-Acetylcysteine

NAC increases glutathione and influences redox systems.

Since oxidative stress plays only a minor role, a relevant reduction in efficacy appears less likely than with anthracyclines or proteasome inhibitors.

low to medium relevance.

Alpha-lipoic acid

Alpha-lipoic acid is frequently used for polyneuropathies.

A relevant weakening of the antitumoral effect has not been convincingly demonstrated so far.

low relevance.

Vitamin E

Vitamin E has been repeatedly investigated for the prevention or treatment of chemotherapy-induced neuropathies.

The data situation is inconsistent, but a relevant interaction with tumor therapy has not been established.

low relevance.

Selenium

No known direct interaction.

low relevance.

Coenzyme Q10

Coenzyme Q10 is occasionally used for fatigue or mitochondrial support.

No relevant influence on the efficacy of vinca alkaloids has been demonstrated to date.

low relevance.

Omega-3 fatty acids

Are often used as a supportive measure.

There is currently no substantiation for a relevant reduction in efficacy.

low relevance.

EGCG (Green Tea Extract)

Unlike with bortezomib, there is no known direct chemical interaction.

Theoretically, cellular signaling pathways can be influenced, but the clinical relevance appears to be low.

low to medium relevance.

Pharmacokinetic peculiarities

Many vinca alkaloids are found in:

• CYP3A4
• P-glycoprotein

metabolized or transported.

Therefore, certain dietary supplements can theoretically influence drug levels.

Particularly relevant are:

• St. John's wort (CYP3A4 induction)
• high-dose green tea extracts
• specific plant extracts with CYP effects

This issue is usually more important than antioxidant properties.

Conclusion

Vinca alkaloids work by inhibiting microtubule formation, thereby causing mitotic arrest with subsequent apoptosis. Although oxidative stress is observed in some models, it is not considered a central mechanism of action. A weakening of the antitumoral effect by antioxidant supplements therefore appears biologically implausible and likely less significant than with taxanes, platinum compounds, proteasome inhibitors, or anthracyclines. The clinically more important potential interactions concern pharmacokinetic effects via CYP3A4 and P-glycoprotein. Overall, vinca alkaloids belong to the tumor therapy classes with a low theoretical probability of interaction with antioxidant supplements.

Cytotoxic antibiotics

Cytotoxic antibiotics are antitumor agents that disrupt DNA function by intercalating into DNA, forming free radicals, or inducing DNA strand breaks, thereby inhibiting the cell division of cancer cells and triggering apoptosis.

• Bleomycin (Bleomycin Baxter®)
• Dactinomycin (Cosmegen®, no longer commercially available)
• Doxorubicin (Adriblastin®, Caelyx®)
• Epirubicin (Farmorubicin®)
• Idarubicin (Zavedos®)
• Mitomycin (Mitem®)
• Mitoxantrone (Novantrone®)

The term cytotoxic antibiotics includes several antineoplastic agents of microbial origin. They belong to the oldest classes of chemotherapy and act predominantly through DNA damage, free radicals, or disturbances of DNA function.

The main representatives include:

Anthracyclines

• Doxorubicin
• Epirubicin
• Daunorubicin
• Idarubicin

Non-anthracycline antibiotics

• Bleomycin
• Mitomycin C
• Dactinomycin
• Plicamycin

Since anthracyclines hold a special position regarding nutraceutical/supplement interactions, a separate discussion is worthwhile.

Anthracyclines

Anthracyclines work through multiple mechanisms simultaneously:

• Intercalation into DNA
• Inhibition of Topoisomerase II
• Formation of free oxygen radicals
• Mitochondrial damage
• Activation of apoptotic signaling pathways

ROS formation is significantly more pronounced in anthracyclines than in most other chemotherapy classes.

This theoretically creates the most plausible basis for interactions with antioxidants.

This is why anthracyclines are traditionally at the center of the discussion about NMEs and chemotherapy.

Cytotoxic antibiotics and supplements

vitamin C

Neutralizes free radicals.

Theoretically, there is a possibility of weakening ROS-mediated cytotoxicity.

→ Medium to high theoretical relevance.

NAC

Increases intracellular glutathione.

Since oxidative stress is a relevant mechanism of action, an interaction appears biologically plausible.

→ high theoretical relevance.

Alpha-lipoic acid

Has antioxidant effects and influences mitochondrial processes.

medium to high relevance.

Vitamin E

Fat-soluble antioxidant.

It is often discussed because of possible cardioprotection.

medium relevance.

Coenzyme Q10

Specifically investigated for anthracycline cardiotoxicity.

medium relevance.

Selenium

Antioxidant enzyme systems are supported.

low to medium relevance.

The Special Case of Bleomycin

Bleomycin works by forming free radicals that cause DNA strand breaks.

Here, ROS are not just accompanying phenomena, but are immediately involved in the mechanism of action.

This theoretically also leads to increased sensitivity to strongly antioxidant supplements.

However, radical formation differs mechanistically from that of anthracyclines.

Pulmonary toxicity

The most important side effect of bleomycin is:

• Interstitial Pneumonitis
• Pulmonary fibrosis

This is why antioxidant strategies are sometimes discussed as a protective measure.

Here arises the classic problem: Protection of healthy tissue versus possible weakening of the tumor effect.

Mitomycin C

Mitomycin C primarily acts by:

• DNA cross-links
• Inhibition of DNA synthesis

Oxidative stress plays a lesser role than with anthracyclines or bleomycin.

Therefore, interactions with antioxidants appear less likely.

Dactinomycin

Dactinomycin directly binds to DNA and inhibits RNA synthesis.

ROS are not a central mechanism of action.

The theoretical probability of interaction with antioxidants is therefore low.

Evaluation of Individual NEMs – Overall Consideration

vitamin C

• Anthracyclines: moderate to high
• Bleomycin: medium
• Mitomycin/Dactinomycin: low

→ overall medium relevance.

NAC

• strongest theoretical relevance within the usual NEM

medium to high.

Alpha-lipoic acid

medium.

Vitamin E

low to medium.

Coenzyme Q10

low to medium.

Selenium

→ low.

EGCG (Green Tea Extract)

No established direct interaction known.

Theoretical redox effects possible.

low to medium.

Conclusion

Cytotoxic antibiotics do not form a uniform drug class regarding possible interactions with dietary supplements. While anthracyclines and, to a lesser extent, bleomycin utilize oxidative stress and free radicals directly for tumor cell damage, the effects of mitomycin C or dactinomycin are predominantly based on DNA binding or DNA damage, respectively. Therefore, a weakening of the antitumor effect by strongly antioxidant dietary supplements, particularly with anthracyclines, appears biologically plausible. Substances such as NAC, high-dose vitamin C, alpha-lipoic acid, or vitamin E have the highest theoretical relevance here. Overall, anthracyclines represent the tumor therapy class with the greatest theoretical probability of interaction with antioxidant dietary supplements.

Mechanisms

The active ingredients used each target different points of attack, which are briefly described below.

Purine synthesis

Purine synthesis inhibitors block the formation of purine nucleotides, thereby preventing DNA and RNA synthesis. This inhibits cell division and promotes the death of cancer cells.

Dihydrofolate reductase

Dihydrofolate reductase (DHFR) is an enzyme that reduces dihydrofolate to tetrahydrofolate. Tetrahydrofolate is required for the synthesis of purines and thymine and is therefore essential for DNA synthesis and cell division.

Ribonucleotides

Ribonucleotides are the building blocks of RNA. They consist of a base (Adeny, Gguanani, Cytosin and Uracil), Ribose (sugar) and one or more phosphate group(s) and also serve as precursors for the formation of DNA building blocks.

Examples:

• Adenosine monophosphate (AMP)
• Guanosine monophosphate (GMP)
• Cytidine monophosphate (CMP)
• Uridine monophosphate (UMP)

Thymidylate Synthase

Thymidylate synthase is an enzyme that converts dUMP (deoxyuridine monophosphate) to dTMP (deoxythymidine monophosphate), thus enabling the formation of the DNA building block thymine. Its inhibition leads to a disruption of DNA synthesis and prevents cell division.

Deoxyribonucleotides

Deoxyribonucleotides are the building blocks of DNA. It consists of a base (dATP – Adenine, dGTP – Guanin, dCTP – Cytosin and dTTP – T(nucleotides), Deoxyribose (sugar), and phosphate, and are needed for the duplication of genetic material.

DNA synthesis

DNA synthesis is the duplication of DNA during the S (synthesis) phase of the cell cycle, in which two identical copies are produced from one DNA molecule.

DNA adducts

DNA adducts are covalent bonds of chemical substances to DNA bases, which alter DNA structure and interfere with replication and transcription, thereby triggering apoptosis.

Protein synthesis

Protein synthesis is the production of proteins using genetic information from DNA, consisting of transcription (DNA → mRNA) and translation (mRNA → protein).

Cell cycle checkpoints

Cell cycle checkpoints are control mechanisms that halt the cell cycle at specific points to repair DNA damage or prevent faulty cell division.

The five most important control points are:

• G1 checkpoint (before DNA synthesis) checks
  Cell size
  – Nutrients/Energy
  DNA damage
  Decision:
  – Entry into S-phase (DNA synthesis or cell cycle arrest, or repair
• S phase Quality control during DNA replication checks whether:
  – the DNA is correctly duplicated
  – replication errors occur
• G2-Checkpoint (before mitosis) checks:
  is the DNA completely duplicated?
  – are there any damages?
  Decision:
  – Repair or cell cycle arrest
• M-Control Point (Metaphase) Checkpoint Checks:
  – are all chromosomes correctly attached to the spindle apparatus?
  Decision:
  – if OK – Start of anaphase (separation of chromosomes)
  – if errors
  Repair attempt
  – – Repair not possible, then permanent blockade (arrest)
  – – Apoptosis

Signaling

Signaling at the M-checkpoint is the transmission of molecular signals that monitor the correct attachment of chromosomes to the spindle apparatus and, in case of errors, stop the cell cycle by inhibiting the APC/C complex (Anaphase-Promoting Complex).

Dietary supplements

Although oncologists try to assemble the „optimal“ combination of cytostatics for each specific use case and patient condition for a largely gentle chemotherapy, there is no chemotherapy that comes without side effects that are recognized as „gentle“ from the patient's perspective.

Furthermore, oncologists mostly dislike it when patients or their relatives come up with well-intentioned ideas, especially concerning supplements.

The thought of wanting to do a lot for cell protection after learning that chemotherapy also attacks the body's good and important (rapidly dividing) cells is quite understandable.

However, if one thinks this idea through to the end, one must acknowledge that antioxidant-acting nutritional supplements run counter to massively oxidizing cytostatics: the high-level oxidative cellular stress induced by chemotherapy drugs is intended to destroy the tumor cells by causing them to die.

The dosage of these cytostatics is calculated to evoke this exact effect with the resulting stress level.

From an oncological perspective, antioxidant-acting dietary supplements can therefore be counterproductive. Since many chemotherapy and radiation therapies destroy tumor cells through oxidative stress, there is a risk that high-dose antioxidants, because they, like most cytostatics, do not distinguish between healthy and tumor tissue, will also protect the cancer cells from the therapy, thus reducing the success of the treatment.

Example: A large study by the German Cancer Research Center (MARIE study by Audrey Y Jung effective from 01.01.2019 Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy) showed that taking antioxidants during of therapy in breast cancer patients with a 1.6-fold increased mortality and one 1.8 times higher relapse rate was connected.

While some cytostatic drugs exert their antitumor effect at least partly through the induction of oxidative stress, antimetabolites and mitotic inhibitors primarily act by disrupting DNA synthesis or cell division, respectively. While oxidative stress can also occur with these agents, it is not considered their dominant mechanism of action.

A nutraceutical can be problematic if it influences the tumor effect of the chemotherapy drug, but it can also be very useful if it specifically reduces organ damage.

Examples of NEM

N-Acetylcysteine (NAC)

• Strong redox-modulating potential.
• Most commonly associated with reduced chemotherapy efficacy in preclinical studies.

High-dose Vitamin C

• Particularly controversial.
• In vitro, partly protective for tumor cells, partly even antitumor.

Vitamin E

• Mixed data.
• Often studied for reducing neurotoxicity.

Selenium

• More in the context of side effect reduction investigated.
• Few indications of loss of efficacy.

Coenzyme Q10

• Primarily of interest due to potential cardioprotection with anthracyclines.
• So far, little evidence of negative interactions.

Examples of indications

• Neuropathy - Alpha-lipoic acid, B vitamins
• Fatigue – Carnitine, Coenzyme Q10
• Mucositis – Glutamine
• Selenium deficiency - Selenium
• Vitamin D Deficiency - Vitamin D

Cytostatics with primarily non-oxidative effects

For the following cytostatics, there is currently no convincing evidence that standard antioxidant supplementation fundamentally impairs their effectiveness:

• Methotrexate – Inhibition of nucleotide synthesis
• 5-Fluorouracil – Thymidylate Synthase Inhibition
• Capecitabine – Prodrug of 5-FU
• Cytarabine - DNA Synthesis Inhibition
• Vincristine – Microtubule Inhibition
• Vinblastine - Microtubule Inhibition
• Paclitaxel – Microtubule Stabilization
• Docetaxel – Microtubule Stabilization

Conclusion

Ultimately, the assessment of antioxidant dietary supplements during chemotherapy should not be made across the board, but rather based on the mechanism of action of the cytostatic drug, the antioxidant potency and dosage of the supplement, possible pharmacokinetic interactions, the state of clinical evidence, and the therapeutic goals of supplementation.

Chemo – Therapie Konfigurator – Klinik

Every chemotherapy treatment is individual – just like the underlying cancer. Accordingly, different active agents are used, often in combination as well.

The configurator below allows for the individual selection of cytostatics used in each treatment case. The expected hematological courses, nadir time points, and other relevant laboratory parameters and their development are displayed on the timeline of a therapy cycle.

The displayed data is based on published studies, professional information, and schematic modeling. It serves as a guide for patients and their relatives to better understand changes in laboratory values and potential side effects.

In consultation with the attending physicians, this can help to detect critical phases early, initiate supportive measures in a timely manner, and accompany the therapy as safely and effectively as possible without compromising the treatment success.

Anyone affected and – additionally – seeking professional advice can at any time receive individual Consulting and/or research requests.

Visualisierer

Anleitung – Chemo-Visualisierer

Schnell-Anleitung für Kliniker

KURZANLEITUNG KLINIKER – Chemotherapie-Visualisierer v5.0

• Wirkstoffauswahl
  60 Wirkstoffe aus 11 Klassen per Freitextsuche oder Kategoriefilter auswählbar. Mehrfachauswahl möglich — die Visualisierung zeigt automatisch die kombinierte Toxizitätshüllkurve (Worst-case-Modell).
• Schema laden
  Tab „Indikation / Schema": 33 hinterlegte Protokolle (R-CHOP, FOLFOX, BEACOPP, AC-T u.a.) mit Leitlinien-Links (ESMO, NCCN) und Schlüsselstudien. Klick auf „Laden" setzt automatisch alle Wirkstoffe und die schematypische Zykluslänge.
• Vergleichsmodus A|B
  Tab „Vergleich A|B": Simultaner Toxizitätsvergleich zweier Schemata — FN-Risiko, emetogenes Potenzial, ANC-Nadir und Organtoxizitätsprofil nebeneinander, farbkodiert nach günstigerem Wert.
• Patient profile
  BSA (DuBois oder Mosteller), eGFR (CKD-EPI 2021), Child-Pugh A/B/C und Baseline-Laborwerte eingeben. Alle Dosisanpassungs-Badges, Kurven und Calvert-Formel (Carboplatin) reagieren sofort.
• FN-Risiko
  Automatische Risikostratifizierung nach EORTC 2011 und ASCO 2015. G-CSF-Primärprophylaxe wird ab >20 % empfohlen. Bei Bleomycin-haltigen Schemata erscheint automatisch der Hinweis „KEIN G-CSF".
• Antiemese
  Vollständiges Regime nach MASCC/ASCO 2020/NCCN v2.2024 — 5-HT3-Antagonist, NK1-Antagonist, Dexamethason, Olanzapin bei Cisplatin. Das AC-Schema wird automatisch als hoch emetogen eingestuft.
• TLS-Risiko
  Cairo-Bishop-Klassifikation mit substanzspezifischen Risikopunkten. Bei hohem Risiko (z.B. Venetoclax Ramp-up, Rituximab bei großer Tumorlast): Allopurinol, Hyperhydrierung ≥2–3 L/m²/d, Rasburicase bei Harnsäure >476 µmol/L.
• Dosisanpassung Leberinsuffizienz
  Erscheint automatisch bei hepatisch metabolisierten Wirkstoffen oder Child-Pugh B/C. Zeigt für 19 Wirkstoffe den restriktivsten Faktor aus Bilirubin-Schwelle und Child-Pugh-Klasse — mit direkt klickbaren FDA-PI-Quellenlinks.
• Pharmakogenetik
  UGT1A1 (Irinotecan), TPMT/NUDT15 (Thiopurine), DPYD (Fluoropyrimidine, 4-Varianten-Panel nach FDA 2022), CYP3A4/CYP2D6 — Phänotyp wählen, Dosisempfehlung nach CPIC-Leitlinien erscheint sofort.
• Supportive-Care-Panel (3-stufig)
  Checkbox „Supportive Care" aktivieren: Stufe 1 zeigt obligate Begleitmedikamente je Wirkstoff, Stufe 2 die NEM-Datenbank (26 Einträge, evidenzbasiert, mit PMIDs), Stufe 3 die Ätherische-Öle-Datenbank (10 Einträge, nach Evidenzlevel klinisch/präklinisch/in vitro).
• NEM-Timing-Kontraindikationen
  Selen ≥24h Abstand zu Alkylanzien · NAC nicht zeitgleich mit Alkylanzien/Cisplatin · Vitamin C i.v. ≥48h Abstand zu Anthrazyklinen/Alkylanzien · ALA 4–6h Abstand zu Oxaliplatin · Curcumin 4–6h Abstand zu Cyclophosphamid/Doxorubicin · Probiotika KI bei ANC <0,5 G/L.
• CYP-Interaktionen (NEM × Zytostatika)
  Quercetin: CYP3A4-Inhibition → Paclitaxel/Docetaxel-Spiegel ↑ · Berberin: CYP3A4/CYP2D6-Inhibition → cave Taxane, Vincristin · Boswellia oral: CYP3A4-Inhibition → cave Taxane · Ingwer oral >2 g/d: Blutungszeit ↑, 4h Abstand zu Taxanen.
• Qualitätsanforderung Ätherische Öle
  Für orale Einnahme kommen ausschließlich ätherische Öle in Frage, die eine chargenbezogene GC/MS-Analyse vorweisen und als Lebensmittel bzw. Nahrungsergänzungsmittel zugelassen sind. Produkte ohne diesen Nachweis sind nicht für die innere Anwendung geeignet.
• PDF-Export (Kurvenreport inkl. Supplements)
  Button „PDF-Export" erzeugt druckfertigen Bericht mit allen SVG-Kurven, Patientenprofil, Anthrazyklin-Kumulativdosis, NEM-Tabellen mit PMIDs und EO-Tabellen nach Evidenzlevel. Popup-Blocker ggf. deaktivieren; Hintergrundgrafiken beim Drucken aktivieren.
• ECOG Performance Status
  Radiobuttons 0–4 im PP-Panel. ECOG ≥ 2 erzeugt automatisch eine Warnung in allen Kurven-Hover-Popups ("FN-Risiko erhöht · Dosisreduktion erwägen") und ein farbiges Badge. Beeinflusst die Gesamtrisikobeurteilung im AI-Prognose-Panel.
• Kachexie-Monitoring (Gewichtsverlauf)
  Vorgewicht (kg) und Zeitraum (Monate) eingeben. Automatische Klassifikation nach ESPEN Oncology 2021: <2% stabil / 2–5% moderat (Ernährungsberatung) / 5–10% signifikant (Ernährungsintervention obligat) / >10% schwere Kachexie (interdisziplinär).
• Vorherige Anthrazyklin-Exposition
  Wirkstoff und kumulative Vordosis eingeben. Die Vordosis wird automatisch in den Anthrazyklin-Kumulativdosis-Gauge eingerechnet. Limits: Doxorubicin 450 mg/m² · Epirubicin 900 mg/m² · Daunorubicin 600 mg/m² · Idarubicin 150 mg/m² · Mitoxantron 140 mg/m².
• Hb-Transfusions-/EPO-Trigger
  Einstellbare Hb-Schwelle (Standard 8,0 g/dL; ASCO 2019 PMID 30714878) erscheint als orangefarbene gestrichelte Linie in der Hb-Kurve. Badge-Warnung wenn Baseline-Hb bereits unter Trigger. Leitlinie: EPO-Therapie bei Hb <10 g/dL unter Chemo (ESMO 2018).
• Tagesmarker (Datum & Zyklusposition)
  Datum Chemo-Gabe (Tag 1) + Datum Blutabnahme + Zyklus Z1–Z8 eingeben. Berechnet Tag im Zyklus und zeichnet senkrechten Marker + waagrechten Strich auf Messwert-Höhe in alle Kurven. Im Mehrzyklus-Modus korrekte absolute Tagesposition (z.B. Zyklus 3 Tag 12 = absoluter Tag 54 bei 21-Tage-Schema).
• Hover-Popup: Literatur-Bar und ECOG-Warnung
  Alle Kurven-Popups zeigen automatisch eine klickbare Literatur-Leiste mit allen im Popup enthaltenen PubMed-Links. Bei ECOG ≥ 2 erscheint im Popup eine orangefarbene klinische Warnung. Ideal für Lehrveranstaltungen und strukturierte Fallbesprechungen.
• Profil speichern / laden (IndexedDB)
  Im PP-Panel oben: Name/Kennung eingeben → 💾 Speichern sichert alle PP-Felder, Laborwerte, Datum, Zyklus und Wirkstoffe im Browser. 📂 Laden zeigt alle gespeicherten Profile zur Auswahl. Daten bleiben nach Browser-Schließen erhalten. Funktioniert nur über Webserver (nicht als lokale Datei). Tipp: je Zyklus ein separates Profil anlegen.
• Zyklus-Anzeige-Filter Z1–Z8 (entkoppelt)
  Neben dem PDF-Export-Button: Checkboxen Z1–Z8 steuern welche Zyklen im Zeitstrahl dargestellt werden (unabhängig vom Zyklus-Selector oben). Beispiel: Z1+Z2+Z3 → nur Kurven und Tagesmarker der Zyklen 1–3 sichtbar. "Alle Zyklen" hakt alle Z1–Z8 gleichzeitig an.
• Immuntherapie — Checkpoint-Inhibitoren (9 Wirkstoffe)
  Tab "Checkpoint-Inhibitor" im Wirkstoffgitter oder "Immuntherapie" in Indikation/Schema. PD-1 (Pembrolizumab, Nivolumab, Cemiplimab), PD-L1 (Atezolizumab, Durvalumab, Avelumab), CTLA-4 (Ipilimumab, Tremelimumab), LAG-3 (Relatlimab). Kurven zeigen irAE-Risikoprofile (TSH, ALT, Kreatinin, Troponin, Glukose) mit Onset/Peak/Persistenz — nicht klassische Nadir-Kurven. 17 Schemata (KEYNOTE-024, CheckMate 227, RELATIVITY-047 etc.).
• Monoklonale AK (36 Wirkstoffe, Tab "Monoklonale AK")
  Anti-HER2: Trastuzumab, Pertuzumab, T-DM1, T-DXd, Margetuximab, Tucatinib. Anti-VEGF: Bevacizumab, Ramucirumab. Anti-EGFR: Cetuximab, Panitumumab, Amivantamab. Bispezifische AK: Teclistamab, Mosunetuzumab, Epcoritamab, Glofitamab, Blinatumomab, Elranatamab, Linvoseltamab. ADCs: T-DM1, T-DXd, Sacituzumab, Enfortumab, Mirvetuximab, Loncastuximab, Belantamab, Inotuzumab, Gemtuzumab, Ifinatamab. Sonstige: Denosumab, Elotuzumab, Ofatumumab, Dinutuximab. 24 Schemata inkl. CLEOPATRA, EMILIA, DESTINY-Breast03, HER2CLIMB, ASCENT, EV-302 etc.
• CAR-T-Zelltherapien (6 Wirkstoffe, Tab "CAR-T")
  CD19: Tisagenlecleucel (Kymriah), Axicabtagene (Yescarta), Lisocabtagene (Breyanzi), Brexucabtagene (Tecartus). Anti-BCMA: Idecabtagene (Abecma), Ciltacabtagene (Carvykti). Kurven: schwere Zytopenie nach Lymphodepletion + CRS-Risikofenster (Lymphozyten, Troponin). 6 Schemata inkl. JULIET, ZUMA-1/2/7, TRANSFORM, KarMMa, CARTITUDE-1/4. Stationaere Aufnahme und REMS-Anforderungen in Notizen dokumentiert.
• irAE-Kurvenmodus (neuer pt-Typ "irae")
  Fuer Checkpoint-Inhibitoren und monoklonale AK: Kurven zeigen typischen Verlauf immunvermittelter Nebenwirkungen — Onset-Tag, Peak-Tag, persistentes Niveau. TSH sinkt (Hypothyreose), ALT/Kreatinin/Glukose/Troponin/Lipase steigen. Zeitachse in Wochen statt Tagen (21-Tage-Zyklus = Wochen 1–3). Hover-Popup zeigt Inzidenz, Grad 3–4-Rate und Literaturlink.
• Limitations
  Hämatologische Kurven sind populationsbasierte Medianwerte — erhebliche inter-individuelle Variabilität. [S]-Kurven sind interpoliert, keine prospektiven Tageswerte. Wechselwirkungsdatenbank nicht vollständig — kein Ersatz für DRUGDEX/Lexicomp. Alle Entscheidungen verbleiben beim behandelnden Fachpersonal.

'; // -- 7. Open print window ---------------------------------------------- var pdfBlob = new Blob([html], {type: 'text/html;charset=utf-8'}); var pdfUrl = URL.createObjectURL(pdfBlob); var printWindow = window.open(pdfUrl, '_blank'); if (!printWindow) { alert('Popup-Blocker aktiv \u2013 bitte Popups f\u00fcr diese Seite erlauben.'); URL.revokeObjectURL(pdfUrl); return; } printWindow.addEventListener('load', function() { setTimeout(function(){ printWindow.focus(); printWindow.print(); URL.revokeObjectURL(pdfUrl); }, 300); }); } // --- INSTITUTIONAL REPORTS ------------------------------------------------ function generateInstitutionalReport() { loadPatientRegistry(); if (Object.keys(patientRegistry).length === 0) { alert('No patients in registry'); return; } var patients = Object.values(patientRegistry); var html = ''; html += '

Anleitung – Patienteninformations-Panel

Important note: Das Patienten-Informations-Panel dient der Vorbereitung und Nachbereitung von Arztgesprächen. Es ersetzt nicht das Gespräch mit dem Behandlungsteam. Alle Angaben beruhen auf klinisch validierten Daten aus FDA-Fachinformationen, CTCAE v5 und DGHO-Patienteninformationen. Bei akuten Beschwerden immer das Behandlungsteam kontaktieren.

1. Zweck und Abgrenzung

Das Patienten-Informations-Panel ist ein eigenständiges HTML-Panel, das neben dem Chemotherapie-Visualisierer eingebettet werden kann. Es übersetzt die klinischen Daten des Visualisierers automatisch in verständliche Alltagssprache — ohne pharmakologisches Vorwissen vorauszusetzen.

Es richtet sich an Patientinnen und Patienten, die ihre Therapie besser verstehen, sich gezielter auf Arztgespräche vorbereiten oder ihre Kontrolltermine eigenständig nachvollziehen möchten.

Aspect	Kliniker-Tool (Visualisierer)	Patienten-Panel
Language	Fachsprache, pharmakologische Parameter	Alltagssprache, konkrete Handlungsanweisungen
Target group	Ärzte, Pflegefachkräfte, Lehrende	Patientinnen und Patienten, Angehörige
Contents	Nadir-Fraktionen, GFR, Dosisanpassung, PK	Was tun bei Fieber? Wann zum Arzt? Was darf ich essen?
Datenquelle	Dieselbe (FDA PI, CTCAE, Leitlinien)	Dieselbe — aber in einfacher Sprache aufbereitet
Validierung	Klinisch-pharmakologisch	Klinisch-pharmakologisch + Patientenverständlichkeit

Das Panel ist ein Informations- und Aufklärungswerkzeug, kein medizinisches Diagnose- oder Therapieinstrument. Es trifft keine Therapieentscheidungen und gibt keine individualisierten medizinischen Empfehlungen.

2. Was das Panel anzeigt

Sobald im Visualisierer Wirkstoffe ausgewählt oder ein Schema geladen wird, aktualisiert sich das Patienten-Panel automatisch. Es zeigt zehn Informationsbereiche:

Area	Was der Patient sieht	Wissenschaftliche Grundlage
Ihre Medikamente	Name, verständliche Erklärung jedes Wirkstoffs, Anwendungsweg	FDA PI; DGHO-Patienteninformationen
Therapieplan	Zykluslänge, Anzahl Zyklen, Gesamtdauer in Wochen	Aus Visualisierer-Einstellungen (Zyklus, Zykluslänge)
Blutbild und Infektschutz	Wann das Blutbild am niedrigsten ist ("Nadir Tag X"), Infektionsrisiko in Ampelfarben, Fieber-Notfallhinweis	Nadir-Tage aus FDA PI; FN-Risiko nach EORTC 2011
Übelkeit und Ernährung	Wie stark Übelkeit zu erwarten ist, welche Medikamente helfen, praktische Ernährungstipps	Hesketh-Klassifikation; ASCO 2020
Mögliche Nebenwirkungen	Häufige Nebenwirkungen in einfacher Sprache pro Wirkstoff	CTCAE v5; FDA PI; DGHO-Patienteninformationen
Protective measures	Was der Patient aktiv tun kann (Trinken, Mundpflege, Kälteschutz)	FDA PI; klinische Praxisempfehlungen
Kontrolltermine	Empfohlene Blutbild-Kontrolltage als visueller Kalender, Nadir-Nähe markiert	NCCN Myelosuppression 2024; FDA PI
Special Notes	Substanzspezifische Warnungen (Kälte bei Oxaliplatin, Lungenschutz bei Bleomycin, irAE bei Immuntherapie)	FDA PI, Leitlinien
Wann sofort handeln	Sechs Notfallsituationen mit klaren Handlungsanweisungen	CTCAE v5; Onkologische Notfallmedizin
Alltag und Lebensqualität	Bewegung, Ernährung, Mundpflege, Sonnenschutz, Nahrungsergänzung	ESPEN 2021; ASCO Patient Guides; DGHO
Obligate Begleitmedikamente	Welche Medikamente zwingend zur Chemotherapie gehören — farblich nach Wirkstoff	FDA PI; substanzspezifisch
Supplement-Empfehlungen (NEM)	26 evidenzbasierte Supplemente — Dosierung, Timing, PubMed-Link; CAVE-Hinweise rot	PubMed-verifiziert; RCTs
Ätherische Öle (Aromatherapie)	3 Evidenzlevel: klinisch / präklinisch / nur in vitro; GC/MS-Qualitätshinweis	10 Einträge; PubMed-verifiziert

Neue Funktionen ab Version 5.1

Das Panel zeigt nun weitere personalisierte Informationsbereiche wenn die entsprechenden Daten im Profil eingetragen wurden:

Neuer Bereich	Was Sie sehen und was es bedeutet
Mein Aktivitätslevel (ECOG)	Ihr Aktivitätslevel (0 = voll aktiv bis 4 = bettlägerig) beeinflusst das Infektionsrisiko. Bei eingeschränktem Aktivitätslevel (ECOG ≥ 2) erscheint automatisch ein Hinweis in den Kurven-Informationen.
Gewichtsverlauf	Wenn Sie Ihr Vorgewicht und den Zeitraum eintragen, berechnet das Panel den Gewichtsverlust. Ab 5% Verlust in 3 Monaten wird eine Ernährungsberatung empfohlen (internationale Leitlinie ESPEN 2021).
Frühere Herzmedikament-Belastung	Wenn Sie früher bereits ein Anthrazyklin (herzbelastendes Chemotherapie-Medikament) erhalten haben, wird die frühere Dosis in die Berechnung der Gesamtbelastung einbezogen.
Blutungsschwelle (Hb-Trigger)	Eine einstellbare Schwelle (Standard 8,0 g/dL) erscheint als orangefarbene Linie in Ihrer Hämoglobin-Kurve. Fällt Ihr Blutfarbstoff unter diese Linie, kann eine Bluttransfusion oder eine blutbildstimulierende Spritze (EPO) nötig werden.
Mein heutiger Tag im Zyklus	Wenn Sie das Datum Ihrer Chemotherapie-Gabe, das Datum Ihrer letzten Blutabnahme und Ihren aktuellen Zyklus eintragen, erscheint auf jeder Blutwert-Kurve eine schwarze Markierung — genau an dem Tag, an dem Ihr Blut abgenommen wurde. So sehen Sie sofort wo Sie sich auf der Kurve befinden.

2b. Meine Daten speichern und laden

Im Bereich "Patientenprofil & Organfunktion" gibt es oben ein neues Feld für Ihren Namen oder eine Kennung sowie drei Schaltflächen zum Speichern, Laden und Löschen Ihrer Daten.

button	What is happening
💾 Speichern / Save	Alle Ihre eingetragenen Werte (Laborwerte, Gewicht, Datum, Zyklus) werden unter dem eingegebenen Namen dauerhaft im Browser gespeichert. Die Daten bleiben auch nach dem Schließen des Browsers erhalten.
📂 Laden / Load	Zeigt eine Liste aller gespeicherten Profile. Klicken Sie auf einen Eintrag um alle Daten wiederherzustellen — zum Beispiel um die Werte eines früheren Zyklus erneut anzuschauen.
🗑️ Löschen	Löscht das Profil mit dem aktuellen Namen nach einer Sicherheitsabfrage.

Tip: Speichern Sie die Daten jedes Zyklus unter einem eigenen Namen (z.B. "Meine Therapie Zyklus 1", "Meine Therapie Zyklus 2") — so können Sie die Verläufe vergleichen und Ihrem Arzt zeigen.

2c. Welche Zyklen soll das Tool anzeigen?

Neben dem Knopf "PDF-Export" befinden sich acht Auswahlkästchen Z1 – Z8. Damit wählen Sie aus welche Zyklen auf dem Zeitstrahl sichtbar sind.

• Z1 allein angehakt → nur der erste Zyklus wird angezeigt
• Z1, Z2, Z3 angehakt → die ersten drei Zyklen werden nebeneinander dargestellt
• All cycles → alle acht Zyklen auf einmal sichtbar

Die Auswahl beeinflusst auch wo der schwarze Tagesmarker (Ihr aktueller Tag im Zyklus) erscheint.

---

2d. Immuntherapie, Antikörper und CAR-T im Visualisierer

Das Tool zeigt jetzt auch moderne Krebstherapien mit Antikörpern und Immuntherapien — nicht nur klassische Chemotherapie. Diese Medikamente wirken anders und haben ein anderes Nebenwirkungsprofil.

Checkpoint-Inhibitoren ("Immuntherapie"-Tab)

Medikamente wie Pembrolizumab (Keytruda), Nivolumab (Opdivo) oder Ipilimumab (Yervoy) aktivieren das Immunsystem gegen Krebszellen. Die Kurven zeigen nicht den klassischen Tiefpunkt der Blutwerte, sondern das typische Zeitfenster möglicher immunbedingter Nebenwirkungen:

• Schilddrüse (TSH): Kann nach 6–12 Wochen sinken (Unterfunktion) → Müdigkeit, Gewichtszunahme
• Leber (ALT): Kann ansteigen (Entzündung) → Gelbfärbung, Übelkeit
• Niere (Kreatinin): Kann ansteigen → Wassereinlagerungen
• Herz (Troponin): Selten, aber ernst → sofort Arzt informieren bei Brustschmerz

Important: Diese Nebenwirkungen entstehen durch das aktivierte Immunsystem — nicht durch direkte Giftwirkung. Sie können noch Monate nach der letzten Gabe auftreten. Regelmäßige Blutkontrollen sind daher besonders wichtig.

Monoklonale Antikörper ("Monoklonale AK"-Tab)

Antikörper wie Trastuzumab (Herceptin, gegen HER2 bei Brustkrebs) oder Bevacizumab (Avastin, gegen Blutgefäßwachstum) haben spezifischere Nebenwirkungsprofile. Die Kurven zeigen je nach Wirkstoff z.B. Herzfunktion (Trastuzumab), Nierenwerte (Bevacizumab) oder Magnesium (Cetuximab).

CAR-T-Zelltherapien ("CAR-T"-Tab)

CAR-T ist eine einmalige Behandlung mit genetisch veränderten eigenen Immunzellen. Die Kurven zeigen zwei Phasen:

• Woche 1–2: Starker Abfall der weißen Blutkörperchen (durch Vorbereitung)
• Tage 1–14: Mögliches Zytokin-Freisetzungssyndrom (CRS) — Fieber, Erschöpfung, Blutdruckabfall

CAR-T-Therapien erfordern immer einen stationären Aufenthalt. Das Tool zeigt die typischen Verläufe zur Information — Ihre behandelnde Klinik überwacht Sie engmaschig.

---

3. Zusammenhang mit dem klinischen Visualisierer

Das Patienten-Panel synchronisiert sich automatisch mit dem klinischen Visualisierer, sobald beide auf derselben WordPress-Seite eingebettet sind. Bei jeder Wirkstoffauswahl oder jedem Schema-Ladevorgang im Visualisierer aktualisiert sich das Patienten-Panel innerhalb von unter einer Sekunde — ohne dass der Patient etwas tun muss.

Klinischer Workflow: Der Arzt wählt das Schema im Visualisierer (z.B. R-CHOP), der Patient sieht unmittelbar darunter die verständliche Erklärung seiner Therapie: was die Medikamente sind, wann das Blutbild am niedrigsten sein wird, an welchen Tagen Blutabnahmen sinnvoll sind, und was bei Fieber zu tun ist.

4. Einbettung in WordPress

Das Patienten-Panel ist eine eigenständige HTML-Datei (patienten-info-panel.html). Es wird als separater Custom HTML-Block auf derselben WordPress-Seite wie der Visualisierer eingebettet. Es benötigt keine eigenen PHP-Dateien.

Schritt	Aktion
1	Datei patienten-info-panel.html öffnen, gesamten Inhalt kopieren
2	Im Gutenberg-Editor neuen Custom HTML-Block einfügen
3	Inhalt einfügen und speichern
4	LiteSpeed Purge All → Seite neu laden
5	Im Visualisierer einen Wirkstoff wählen — das Panel aktualisiert sich automatisch

Positionierung: Das Panel kann direkt unter dem Visualisierer oder auf einer separaten Unterseite eingebettet werden. Auf derselben Seite erfolgt die Synchronisation automatisch per Polling (alle 600 ms). Auf einer anderen Seite kann die Synchronisation über das Browser-Event rcwv:drugschanged erfolgen (wie beim Supplement-Plugin).

5. Wie das Panel Daten empfängt

Das Panel nutzt zwei unabhängige Mechanismen, um die Wirkstoffauswahl des Visualisierers zu empfangen — beide laufen automatisch, ohne zusätzliche Konfiguration:

Mechanism	Wann aktiv	Description
Polling (gleiche Seite)	Immer wenn Visualisierer und Panel auf derselben Seite sind	Das Panel prüft alle 600 ms die globale Variable window.sel des Visualisierers. Bei Änderung wird das Panel sofort neu aufgebaut.
Browser-Event rcwv:drugschanged	Wenn das Event ausgelöst wird (z.B. durch das Supplement-Plugin)	Das Panel hört auf das Custom-Event und aktualisiert sich beim Empfang. Kompatibel mit dem bestehenden Event-System des Visualisierers.

5. Wissenschaftliche Grundlage der Inhalte

Alle Patienteninformationen basieren ausschließlich auf validierten klinischen Quellen. Es werden keine Inhalte erfunden oder aus nicht-validierten Quellen entnommen.

Contents	source
Wirkstoffbeschreibungen (was ist das Medikament)	FDA Prescribing Information (DailyMed); DGHO-Patienteninformationen
Common Side Effects	CTCAE v5 (Common Terminology Criteria for Adverse Events, Version 5.0); FDA PI
Nadir-Zeitpunkte ("Blutbild am niedrigsten um Tag X")	Substanzspezifische nadirDay-Daten aus dem Visualisierer (FDA PI-basiert)
Infektionsrisiko-Ampel	FN-Basisrisiken nach EORTC Guidelines 2011 (PMID 21095116); ASCO 2015 (PMID 25691678)
Übelkeitseinstufung	Hesketh-Klassifikation emetogener Potenziale; ASCO Antiemesis Guidelines 2020 (PMID 32202946)
Empfohlene Kontrolltage	Nadir-Zeitpunkte aus FDA PI; NCCN Myelosuppression Guidelines 2024
Schutzmaßnahmen und Verhaltenshinweise	FDA PI; ESMO Patient Guides; DGHO-Patienteninformationen
Notfallsituationen	CTCAE v5; Onkologische Notfallmedizin; NCCN
Alltag und Lebensqualität	ESPEN Guidelines Oncology 2021; ASCO Patient Guides; DGHO

Prinzip: Das Panel zeigt nur Informationen an, die durch die vorliegende Wirkstoffauswahl direkt belegt sind. Es erfindet keine Aussagen und macht keine Prognosen über individuelle Krankheitsverläufe.

6. Was das Panel nicht kann und nicht soll

Nicht enthalten	Reason
Individuelle Prognose ("Wie stehen meine Chancen?")	Nicht seriös aus Wirkstoffdaten ableitbar; erfordert Tumorboard, Staging, Molekularpathologie
Dosierungsangaben in mg	Individuell von BSA, GFR und Schema abhängig; nur das Behandlungsteam kann die korrekte Dosis kommunizieren
Empfehlung ob eine Therapie durchgeführt werden soll	Medizinische Entscheidung; nicht Aufgabe eines Informationstools
Aussagen zu Alternativmedizin oder nicht-validierten Therapien	Würde den Rahmen wissenschaftlich valider Information verlassen
Psychologische Beratung oder Krisenintervention	Erfordert qualifizierte Fachpersonen

8. Datenquellen

source	use
FDA Prescribing Information / DailyMed (dailymed.nlm.nih.gov)	Wirkstoffbeschreibungen, Nebenwirkungsprofil, Nadir-Zeitpunkte, Schutzmaßnahmen
CTCAE v5 — Common Terminology Criteria for Adverse Events, Version 5.0 (NCI 2017)	Klassifikation und Beschreibung von Nebenwirkungsschweregraden
EORTC Guidelines 2011 (PMID 21095116)	FN-Basisrisiken; G-CSF-Indikationen
ASCO Antiemesis Guidelines 2020 (PMID 32202946)	Emetogene Potenziale; Antiemese-Regime in Patientensprache
NCCN Myelosuppression Guidelines 2024	Empfohlene Blutbild-Kontrolltage
ESPEN Guidelines Oncology 2021	Ernährungs- und Bewegungsempfehlungen
DGHO-Patienteninformationen (dgho.de)	Sprachliche Vorbilder für verständliche Erklärungen
ASCO Patient Guides (cancer.net)	Alltagsempfehlungen und Verhaltenshinweise
Brock et al., JCO 2012 (PMID 22393086)	Graduierung Cisplatin-Ototoxizität
Bhatt et al., Lancet Oncol 2020 (PMID 32171057)	Natriumthiosulfat-Prävention Cisplatin-Ototoxizität bei Kindern
Superfin et al., Ann Pharmacother 2007 (PMID 17299011)	Leberinsuffizienz-Dosisanpassung
NEM-Datenbank (26 Einträge, PubMed-verifiziert)	Evidenzbasierte Supplement-Empfehlungen mit Timing-Kontraindikationen
Ätherische Öle-Datenbank (10 Einträge, PubMed-verifiziert)	Komplementäre Aromatherapie nach Evidenzlevel; GC/MS-Qualitätsanforderung

---

Stand: Juni 2026. Angaben ohne Gewähr. Das Panel ist kein zugelassenes Medizinprodukt. Bei akuten Beschwerden immer das Behandlungsteam kontaktieren.